Table 3.
Univariate |
Multivariate |
|||
P value | OR (95%CI) | P value | OR (95%CI) | |
Date of recurrence | 0.006 | 1.00 (1.00-1.00) | 0.79 | |
Age at recurrence (years) | 0.93 | |||
Time from transplant | < 0.001 | 0.977 (0.966-0.988) | 0.001 | 0.977 (0.963-0.991) |
Number of tumours | < 0.001 | 1.01 (1.01-1.02) | 0.33 | |
Size of largest tumour | 0.02 | 1.11 (1.02-1.20) | 0.02 | 1.13 (1.02-1.24) |
Number of organs involved | 0.01 | 1.14 (1.11-1.89) | 0.27 | |
Site of recurrence | ||||
Liver | 0.01 | 1.62 (1.13-2.31) | 0.01 | 1.92 (1.14-3.25) |
Lung | 0.43 | |||
Bone | 0.17 | |||
Peritoneal | 0.46 | |||
Adrenal | 0.52 | |||
Lymph node | 0.49 | |||
AFP upon recurrence | 0.02 | 1.00 (1.00-1.00) | 0.02 | 1.00 (1.00-1.00) |
Immunosuppression after recurrence | ||||
mTOR inhibitor | < 0.001 | 0.485 (0.339-0.695) | 0.04 | 0.482 (0.241-0.966) |
Calcineurin Inhibitor | 0.07 | |||
Tacrolimus trough (μg/L) | 0.002 | 1.13 (1.04-1.22) | 0.16 | |
Treatment | ||||
Surgery | < 0.001 | 0.380 (0.240-0.601) | 0.22 | |
RFA | 0.16 | |||
TACE | 0.32 | |||
Radiotherapy | 0.90 | |||
Targeted therapy | 0.97 | |||
Immunotherapy | 0.80 | |||
Supportive | < 0.001 | 2.34 (1.49-3.67) | 0.73 |
AFP: Alpha-fetoprotein; RFA: Radiofrequency ablation; TACE: Trans-arterial chemoembolization; mTOR: Mammalian target of rapamycin.